Sudden-Onset Disaster Mass-Casualty Incident Response: A Modified Delphi Study on Triage, Prehospital Life Support, and Processes.

The application and provision of prehospital care in disasters and mass-casualty incident response in Europe is currently being explored for opportunities to improve practice. The objective of this translational science study was to align common principles of approach and action and to identify how technology can assist and enhance response. To achieve this objective, the application of a modified Delphi methodology study based on statements derived from key findings of a scoping review was undertaken. This resulted in 18 triage, eight life support and damage control interventions, and 23 process consensus statements. These findings will be utilized in the development of evidence-based prehospital mass-casualty incident response tools and guidelines.

Advancing the scientific study of prehospital mass casualty response through a Translational Science process: the T1 scoping literature review stage.

PURPOSE: The European Union Horizon 2020 research and innovation funding program awarded the NIGHTINGALE grant to develop a toolkit to support first responders engaged in prehospital (PH) mass casualty incident (MCI) response. To reach the projects' objectives, the NIGHTINGALE consortium used a Translational Science (TS) process. The present work is the first TS stage (T1) aimed to extract data relevant for the subsequent modified Delphi study (T2) statements. METHODS: The authors were divided into three work groups (WGs) MCI Triage, PH Life Support and Damage Control (PHLSDC), and PH Processes (PHP). Each WG conducted simultaneous literature searches following the PRISMA extension for scoping reviews. Relevant data were extracted from the included articles and indexed using pre-identified PH MCI response themes and subthemes. RESULTS: The initial search yielded 925 total references to be considered for title and abstract review (MCI Triage 311, PHLSDC 329, PHP 285), then 483 articles for full reference review (MCI Triage 111, PHLSDC 216, PHP 156), and finally 152 articles for the database extraction process (MCI Triage 27, PHLSDC 37, PHP 88). Most frequent subthemes and novel concepts have been identified as a basis for the elaboration of draft statements for the T2 modified Delphi study. CONCLUSION: The three simultaneous scoping reviews allowed the extraction of relevant PH MCI subthemes and novel concepts that will enable the NIGHTINGALE consortium to create scientifically anchored statements in the T2 modified Delphi study.

Experimental evaluation of the impact of low tesla transverse magnetic field on dose distribution in presence of tissue interfaces.

PURPOSE: Aim of this study is to experimental evaluate the impact of a 0.35 T transverse magnetic field on dose distribution in presence of tissue-air and tissue-lung interfaces. METHODS: The investigation was carried out using MRIdian (ViewRay, Cleveland, Ohio) and it consisted of comparing experimental measurements performed by Gafchromic EBT3 film dosimetry, to Montecarlo simulations, carried out in the presence and, as well as, the absence of the magnetic field. A preliminary dose calibration was planned on MRIdian, arranging 3 × 3 cm2 film pieces in a water slab phantom and exposing them at different beam-on times, in a dose range equal to 0.1-12.1 Gy. All experimental measurements were then carried out using the calibrated films and delivering one single beam orthogonally to three different phantoms: without inhomogeneity, with an air gap and with a lung inhomogeneity. The dose distributions measured by EBT3 films in presence of magnetic field were compared to those calculated in the presence and, as well as, the absence of the magnetic field, in terms of gamma analysis. A quantification of electron return effect (ERE) was also performed. RESULTS: All the tested plans considering the magnetic field show a gamma-passing rate higher than 98% for 3%/3 mm gamma analysis. In presence of tissue-air interface, the electron return effect causes an over-dosage of +31.9% at the first interface and an under-dosage of -33% at the second interface. The dosimetric variations in presence of tissue-lung interface results to be smaller (+0.8% first interface, -1.3% second interface). CONCLUSION: The impact of 0.35 T magnetic field is not negligible and it can be effectively modelled by the Montecarlo dose calculation platform available in the MRIdian TPS.

A Feasibility Study for in vivo Dosimetry Procedure in Routine Clinical Practice.

PURPOSE: The aim of the in vivo dosimetry, during the fractionated radiation therapy, is the verification of the correct dose delivery to patient. Nowadays, in vivo dosimetry procedures for photon beams are based on the use of the electronic portal imaging device and dedicated software to elaborate electronic portal imaging device images. METHODS: In total, 8474 in vivo dosimetry tests were carried out for 386 patients treated with 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and volumetric modulated arc therapy techniques, using the SOFTDISO. SOFTDISO is a dedicated software that uses electronic portal imaging device images in order to (1) calculate the R index, that is, the ratio between daily reconstructed dose and the planned one at isocenter and (2) perform a γ-like analysis between the signals, S, of a reference electronic portal imaging device image and that obtained in a daily fraction. It supplies 2 indexes, the percentage γ% of points with γ < 1 and the mean γ value, γmean. In γ-like analysis, the pass criteria for the signals agreement ΔS% and distance to agreement Δd have been selected based on the clinical experience and technology used. The adopted tolerance levels for the 3 indexes were fixed in 0.95 ≤ R ≤ 1.05, γ% ≥ 90%, and γmean ≤ 0.5. RESULTS: The results of R ratio, γ-like, and a visual inspection of these data reported on a monitor screen permitted to individuate 2 classes of errors (1) class 1 that included errors due to inadequate standard quality controls and (2) class 2, due to patient morphological changes. Depending on the technique and anatomical site, a maximum of 18% of tests had at least 1 index out of tolerance; once removed the causes of class-1 errors, almost all patients (except patients with 4 lung and 2 breast cancer treated with 3-dimensional conformal radiotherapy) presented mean indexes values ([Formula: see text], [Formula: see text]%, and [Formula: see text] ) within tolerance at the end of treatment course. Class-2 errors were found in some patients. CONCLUSIONS: The in vivo dosimetry procedure with SOFTDISO resulted easily implementable, able to individuate errors with a limited workload.

Initial clinical experience with Epid-based in-vivo dosimetry for VMAT treatments of head-and-neck tumors.

We evaluated an EPID-based in-vivo dosimetry algorithm (IVD) for complex VMAT treatments in clinical routine. 19 consecutive patients with head-and-neck tumors and treated with Elekta VMAT technique using Simultaneous Integrated Boost strategy were enrolled. In-vivo tests were evaluated by means of (i) ratio R between daily in-vivo isocenter dose and planned dose and (ii) γ-analysis between EPID integral portal images in terms of percentage of points with γ-value smaller than one (γ%) and mean γ-values (γmean), using a global 3%-3 mm criteria. Alert criteria of ±5% for R ratio, γ% < 90% and γmean > 0.67 were chosen. A total of 350 transit EPID images were acquired during the treatment fractions. The overall mean R ratio was equal to 1.002 ± 0.019 (1 SD), with 95.9% of tests within ±5%. The 2D portal images of γ-analysis showed an overall γmean of 0.42 ± 0.16 with 93.3% of tests within alert criteria, and a mean γ% equal to 92.9 ± 5.1% with 85.9% of tests within alert criteria. Relevant discrepancies were observed in three patients: a set-up error was detected for one patient and two patients showed major anatomical variations (weight loss/tumor shrinkage) in the second half of treatment. The results are supplied in quasi real-time, with IVD tests displayed after only 1 minute from the end of arc delivery. This procedure was able to detect when delivery was inconsistent with the original plans, allowing physics and medical staff to promptly act in case of major deviations between measured and planned dose.

Routine EPID in-vivo dosimetry in a reference point for conformal radiotherapy treatments.

In-vivo dosimetry (IVD) in external beam radiotherapy is used to detect major clinically relevant differences between planned and delivered dose. Moreover, a detailed analysis of its results, when routinely reported and discussed by the radiotherapy staff, can limit the likelihood of error transmission to many treatments. A first experience of routine EPID-based IVD in a reference point has been performed in our department for 3D-CRT treatments over a three-year period. More than 14,000 images were acquired and 1287 treatment plans were verified. The IVD checks were obtained three times in the first week and then weekly. Tolerance levels of ± 5% for pelvic-abdomen, head-neck and breast irradiations and ± 6% for lung treatments were adopted for the in-vivo measured dose per fraction. A statistical analysis of the IVD results was performed grouping the data by: anatomical regions, treatment units, open and wedged fields and gantry angles. About 10% of the checked doses per fraction showed dosimetric discrepancies out of the tolerance levels. The causes of the discrepancies were 70% delivery or planning errors, 20% morphological changes and 10% procedural limitations. 41 cases (3.2%) have required special investigations because their in-vivo doses per fraction, averaged over the first three sessions, were out of the tolerance levels and in 19 cases (1.5%) the deviations gave rise to an intervention. Statistically significant differences of average variations between planned and delivered doses were observed for: (i) 30° wedged 10 MV fields with respect to those of other wedged or open 10 MV fields delivered by two linacs, due to the incorrect TPS implementation of that wedge transmission factor; (ii) anterior-posterior and posterior-anterior beams with respect to the other gantry orientations for one linac, due to the beam attenuation introduced by the treatment couch; (iii) lateral fields with respect to medial fields of breast irradiations for all linacs, due to small systematic set-up variations. The analysis of our data shows a substantial homogeneity of the IVD results for all the considered body regions and treatment units. However, the observed discrepancies have supplied indications for taking further steps in the optimization process and in some cases to adopt an adaptive approach.

aSi-EPID transit signal calibration for dynamic beams: a needful step for the IMRT in vivo dosimetry.

This work reports a method based on correlation functions to convert EPID transit signals into in vivo dose values at the isocenter point, D iso, of dynamic IMRT beams supplied by Varian linac. Dose reconstruction for intensity-modulated beams required significant corrections of EPID response, due to the X-ray component transmitted through multileaf collimator. The algorithm was formulated using a set of simulated IMRT beams. The beams were parameterized by means of a fluence inhomogeneity index, FI, introduced to describe the degree of beam modulation with respect to open beams. This way, all dosimetric parameters involved in D iso reconstruction algorithm, such as the correlation functions, the correction factor for EPID to phantom distance and the modulated tissue maximum ratios, were determined as a function of the FI index. Clinical IMRT beams were used to irradiate a homogeneous phantom, and for each beam, the agreement between the reconstructed dose, D iso, and the dose computed by TPS, D iso,TPS, was well within 5 %. Moreover, the average ratios, R, between the D iso, and D iso,TPS, resulted equal to 1.002 ± 0.030. Thirty-five IMRT fields of 5 different patients undergoing radiotherapy for head-neck tumors were tested and the results were displayed on a computer screen after 2 min from the end of the treatment. However, 350 in vivo tests supplied an average ratio R equal to 1.004 ± 0.040. The in vivo dosimetry procedure here presented is among the objectives of a National Project financially supported by the Istituto Nazionale di Fisica Nucleare for the development of in vivo dosimetry procedures (Piermattei et al. in Nucl Instrum Methods Phys Res B 274:42-50, 2012) connected to the Record-Verify system of the radiotherapy center.

Generalized EPID calibration for in vivo transit dosimetry.

Many researchers are studying new in vivo dosimetry methods based on the use of Elelctronic portal imaging devices (EPIDs) that are simple and efficient in their daily use. However the need of time consuming implementation measurements with solid water phantoms for the in vivo dosimetry implementation can discourage someone in their use. In this paper a procedure has been proposed to calibrate aSi EPIDs for in vivo transit dosimetry. The dosimetric equivalence of three aSi Varian EPIDs has been investigated in terms of signal reproducibility and long term stability, signal linearity with MU and dose per pulse and signal dependence on the field dimensions. The signal reproducibility was within ± 0.5% (2SD), while the long term signal stability has been maintained well within ± 2%. The signal linearity with the monitor units (MU) was within ± 2% and within ± 0.5% for the EPIDs controlled by the IAS 2, and IAS 3 respectively. In particular it was verified that the correction factor for the signal linearity with the monitor units, k(lin), is independent of the beam quality, and the dose per pulse absorbed by the EPID. For 6, 10 and 15 MV photon beams, a generalized set of correlation functions F(TPR,w,L) and empirical factors f(TPR,d,L) as a function of the Tissue Phantom Ratio (TPR), the phantom thickness, w, the square field side, L, and the distance, d, between the phantom mid-plane and the isocentre were determined to reconstruct the isocenter dose. The tolerance levels of the present in vivo dosimetry method ranged between ± 5% and ± 6% depending on the tumor body location. In conclusion, the procedure proposed, that use generalized correlation functions, reduces the effort for the in vivo dosimetry method implementation for those photon beams with TPR within ± 0.3% as respect those here used.

A generalized calibration procedure for in vivo transit dosimetry using siemens electronic portal imaging devices.

A practical and accurate generalized in vivo dosimetry procedure has been implemented for Siemens linacs supplying 6, 10, and 15 MV photon beams, equipped with aSi electronic portal imaging devices (EPIDs). The in vivo dosimetry method makes use of correlation ratios between EPID transit signal, s (t) (0) (TPR,w,L), and phantom mid-plane dose, D (0)(TPR,w,L), as functions of phantom thickness, w, square field dimensions, L, and tissue-phantom ratio TPR(20,10). The s (t) (0) (TPR,w,L) and D (0)(TPR,w,L) values were defined to be independent of the EPID sensitivity and monitor unit calibration, while their dependence on TPR(20,10) was investigated to determine a set of generalized correlation ratios to be used for beams with TPR(20,10) falling in the examined range. This way, other radiotherapy centers can use the method with no need to locally perform the whole set of measurements in solid water phantoms, required to implement it. Tolerance levels for 3D conformal treatments, ranging between ±5 and ±6% according to tumor type and location, were estimated for comparison purposes between reconstructed isocenter dose, D (iso), and treatment planning system (TPS) computed dose D (iso,TPS). Finally a dedicated software, interfaceable with record and verify (R&V) systems used in the centers, was developed to obtain in vivo dosimetry results in less than 2 min after beam delivery.

Breast in vivo dosimetry by EPID.

An electronic portal imaging device (EPID) is an effective detector for in vivo transit dosimetry. In fact, it supplies two-dimensional information, does not require special efforts to be used during patient treatment, and can supply data in real time. In the present paper, a new procedure has been proposed to improve the EPID in vivo dosimetry accuracy by taking into account the patient setup variations. The procedure was applied to the breast tangential irradiation for the reconstruction of the dose at the breast midpoint, Dm. In particular, the patient setup variations were accounted for by comparing EPID images versus digitally reconstructed radiographies. In this manner, EPID transit signals were obtained corresponding to the geometrical projections of the breast midpoint on the EPID for each therapy session. At the end, the ratios R between D(m) and the doses computed by the treatment planning system (TPS) at breast midpoints, D(m,TPS), were determined for 800 therapy sessions of 20 patients. Taking into account the method uncertainty, tolerance levels equal to ± 5% have been determined for the ratio R.The improvement of in vivo dosimetry results obtained (taking into account patient misalignment) has been pointed out comparing the R values obtained with and with-out considering patient setup variations. In particular, when patient misalignments were taken into account, the R values were within ± 5% for 93% of the checks; when patient setup variations were not taken into account, the R values were within ± 5% in 72% of the checks. This last result points out that the transit dosimetry method overestimates the dose discrepancies if patient setup variations are not taken into account for dose reconstruction. In this case, larger tolerance levels have to be adopted as a trade-off between workload and ability to detect errors, with the drawback being that some errors (such as the ones in TPS implementation or in beam calibration) cannot be detected, limiting the in vivo dosimetry efficacy.The paper also reports preliminary results about the possibility of reconstructing a dose profile perpendicular to the beam central axis reaching from the apex to the lung and passing through the middle point of the breast by an algorithm, similar to the one used for dose reconstruction at breast midpoint. In particular, the results have shown an accuracy within ± 3% for the dose profile reconstructed in the breast (excluding the interface regions) and an underestimation of the lung dose.

Intensity-modulated radiation therapy with simultaneous integrated boost in unresected left-sided pleural mesothelioma: a case report.

A 77-year-old male patient with unresected malignant pleural mesothelioma, clinical stage T3N0M0 according to the New International Staging System for Diffuse Malignant Pleural Mesothelioma, received intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) after 6 cycles of chemotherapy with cisplatin and pemetrexed. SIB-IMRT delivered 40.5 Gy (1.5 Gy/fraction) to the left pleura and 50 Gy (1.85 Gy/fraction) to the sites of macroscopic disease. Radiotherapy was well tolerated. Two months after the end of radiotherapy the patient showed grade 2 lung toxicity (febrile episodes accompanied by dry cough) that was successfully treated with steroid therapy. Local control lasted for 2 years after SIB-IMRT. Then the tumor recurred marginally to the radiation field and the patient underwent chemotherapy with pemetrexed. Three years from the diagnosis, the patient is alive and in good general condition. He only takes prednisone 5 mg/daily for exertional dyspnea. To the best of our knowledge this is the first reported use of SIB-IMRT in unresected malignant pleural mesothelioma. Considering the dosimetric advantages of SIB-IMRT and the clinical results observed in our patient, additional evaluation of this technique seems justified.

Correlation functions for Elekta aSi EPIDs used as transit dosimeter for open fields.

In-vivo dosimetry techniques are currently being applied only by a few Centers because they require time-consuming implementation measurements, and workload for detector positioning and data analysis. The transit in-vivo dosimetry performed by the electronic portal imaging device (EPID) avoids the problem of solid-state detector positioning on the patient. Moreover, the dosimetric characterization of the recent Elekta aSi EPIDs in terms of signal stability and linearity make these detectors useful for the transit in-vivo dosimetry with 6, 10 and 15 MV photon beams. However, the implementation of the EPID transit dosimetry requires several measurements. Recently, the present authors have developed an in-vivo dosimetry method for 3D CRT based on correlation functions defined by the ratios between the transit signal, st (w,L), by the EPID and the phantom midplane dose, Dm(w,L), at the source to axis distance (SAD) as a function of the phantom thickness, w, and the square field dimensions, L. When the phantom midplane was positioned at distance, d, from the SAD, the ratios st(w,L)/s't(d,w,L) were used to take into account the variation of the scattered photon contributions on the EPID as a function of d and L.The aim of this paper is the implementation of a procedure that uses generalized correlation functions obtained by nine Elekta Precise linac beams. The procedure can be used by other Elekta Precise linacs equipped with the same aSi EPIDs, assuming the stabilities of the beam output factors and the EPID signals. The procedure here reported avoids measurements in solid water equivalent phantoms needed to implement the in-vivo dosimetry method in the radiotherapy department. A tolerance level ranging between ± 5% and ± 6% (depending on the type of tumor) was estimated for the comparison between the reconstructed isocenter dose, Diso, and the computed dose, Diso,TPS, by the treatment planning system (TPS).

Dose-guided radiotherapy for lung tumors.

The transit in vivo dosimetry performed by an electronic portal imaging device (EPID) is a very practical method to check error sources in radiotherapy. Recently, the present authors have developed an in vivo dosimetry method based on correlation functions, F (w, L), defined as the ratio between the transit signal, S(t) (w, L), by the EPID and the mid-plane dose, D(m) (w, L), in a solid water phantom as a function of the phantom thickness, w, and of the field dimensions, L. In particular, generalized correlation functions F (w, L) for 6, 10 and 15 MV X-ray beams supplied by a pilot Varian linac, are here used by other three linacs operating in two centers. This way the workload, due to measurements in solid water phantom, needed to implement the in vivo dosimetry method was avoided. This article reports a feasibility study on the potentiality of this procedure for the adaptive radiotherapy of lung tumors treated by 3D conformal radiotherapy techniques. In particular, the dose reconstruction at the isocenter point D(iso) in the lung tumor has been used as dose-guided radiotherapy (DGRT), to detect the inter-fraction tumor anatomy variations that can require new CT scans and an adaptive plan. When a difference greater than 6% between the predicted dose by the treatment planning system (TPS), D (iso,TPS) and the D(iso) was observed, the clinical action started to detect possible anatomical lung tumor changes. Twelve over twenty patients examined presented in vivo dose discrepancies due to the tumor morphological changes during treatments, and these results were successively confirmed by new CT scans. In this work, for a patient that showed for all beams, D (iso) values over the tolerance level, the new CT scan was used for an adaptive plan. The lung dose volume histogram for D (iso,TPS) = 2 Gy per fraction suggested the adaptive plan. In particular, the lung volume included in 2 Gy increased from 350 cm(3) of the original plan to 550 cm(3) of the hybrid plan, while for the adaptive plan the lung volume included in 2 Gy decreased to 15 cm(3). Moreover, the mean doses to the organs at risk were reduced to 70%. The results of this research show that the DGRT procedure by the D(iso) reconstruction, integrated with radiological imaging, was feasible for periodic investigation on morphological lung tumor changes. This feasibility study takes into account the accuracy of two algorithms based on the pencil beam and collapsed cone convolution models for dose calculations where large density inhomogeneities are present.

Integration between in vivo dosimetry and image guided radiotherapy for lung tumors.

The article reports a feasibility study about the potentiality of an in vivo dosimetry method for the adaptive radiotherapy of the lung tumors treated by 3D conformal radiotherapy techniques (3D CRTs). At the moment image guided radiotherapy (IGRT) has been used for this aim, but it requires taking many periodic radiological images during the treatment that increase workload and patient dose. In vivo dosimetry reported here can reduce the above efforts, alerting the medical staff for the commissioning of new radiological images for an eventual adaptive plan. The in vivo dosimetry method applied on 20 patients makes use of the transit signal St on the beam central axis measured by a small ion chamber positioned on an electronic portal imaging device (EPID) or by the EPID itself. The reconstructed in vivo dosimetry at the isocenter point Diso requires a convolution between the transit signal St and a dose reconstruction factor C that essentially depends on (i) tissue inhomogeneities along the beam central axis and (ii) the in-patient isocenter depth. The C factors, one for every gantry angle, are obtained by processing the patient's computed tomography scan. The method has been recently applied in some Italian centers to check the radiotherapy of pelvis, breast, head, and thorax treatments. In this work the dose reconstruction was carried out in five centers to check the Diso in the lung tumor during the 3D CRT, and the results have been used to detect the interfraction tumor anatomy variations that can require new CT imaging and an adaptive plan. In particular, in three centers a small ion chamber was positioned below the patient and used for the St measurement. In two centers, the St signal was obtained directly by 25 central pixels of an a-Si EPID, equipped with commercial software that enabled its use as a stable detector. A tolerance action level of +/- 6% for every checked beam was assumed. This means that when a difference greater than 6% between the predicted dose by the treatment planning system, Diso,TPS, and the Diso was observed, the clinical action started to detect possible errors. 60% of the patients examined presented morphological changes during the treatment that were checked by the in vivo dosimetry and successively confirmed by the new CT scans. In this work, a patient that showed for all beams Diso values outside the tolerance level, new CT scans were commissioned for an adaptive plan. The lung dose volume histograms (DVHs) for a Diso,TPs=2 Gy for fraction suggested the adaptive plan to reduce the dose in lung tissue. The results of this research show that the dose guided radiotherapy (DGRT) by the Diso reconstruction was feasible for daily or periodic investigation on morphological lung tumor changes. In other words, since during 3D CRT treatments the anatomical lung tumor changes occur frequently, the DGRT can be well integrated with the IGRT.

In patient dose reconstruction using a cine acquisition for dynamic arc radiation therapy.

An amorphous silicon (a-Si) electronic portal imaging device (EPID) was implemented to perform transit in vivo dosimetry for dynamic conformal arc therapy (DCAT). A set of images was acquired for each arc irradiation using the EPID cine acquisition mode, that supplies a frame acquisition rate of one image every 1.66 s, with a monitor unit rate equal to 100 UM/min. In these conditions good signal stability, +/-1% (2SD) evaluated during 3 months, signal reproducibility within +/-0.8% (2SD) and linearity with dose and dose rate within +/-1% (2SD) were obtained. The transit signal, S (t), due to the transmitted radiotherapy beam below a solid phantom, measured by the EPID cine acquisition mode was used to determine, (1) a set of correlation functions, F(w, L), defined as the ratio between S (t) and the dose at half thickness, D (m), measured in solid water phantoms of different thicknesses, w and with square fields of side L, (2) a set of factors, f(d, L), that take into account the different x-ray scatter contribution from the phantom to the S (t) signal as a function of the variation, d, of the air gap between the phantom and the EPID. The reconstruction of the isocenter dose, D (iso), for DCAT was obtained convolving the transit signal values, obtained at different gantry angles, with the respective reconstruction factors determined by a house-made software. The method was applied to a first patient and the results show that the reconstructed D (iso) values can be obtained with an accuracy within +/-5%. In conclusion, it was assessed that an a-Si EPID with the cine acquisition mode is suitable to perform transit in vivo dosimetry for the DCAT therapy.

Real time transit dosimetry for the breath-hold radiotherapy technique: an initial experience.

INTRODUCTION: The breath-hold is one of the techniques to obtain the dose escalation for lung tumors. However, the change of the patient's breath pattern can influence the stability of the inhaled air volume, IAV, used in this work as a surrogate parameter to assure the tumor position reproducibility during dose delivery. MATERIALS AND METHOD: In this paper, an Elekta active breathing coordinator has been used for lung tumor irradiation. This device is not an absolute spirometer and the feasibility study here presented developed (i) the possibility to select a specific range epsilon of IAV values comfortable for the patient and (ii) the ability of a transit signal rate S(t), obtained by a small ion-chamber positioned on the portal image device, to supply in real time the in vivo isocenter dose reproducibility. Indeed, while the selection of the IAV range depends on the patient's ability to follow instructions for breath-hold, the S(t) monitoring can supply to the radiation therapist a surrogate of the tumor irradiation reproducibility. RESULTS: The detection of the S(t) in real time during breath-hold was used to determine the interfraction isocenter dose variations due to the reproducibility of the patient's breathing pattern. The agreement between the reconstructed and planned isocenter dose in breath-hold at the interfraction level was well within 1.5%, while in free breathing a disagreement up to 8% was observed. The standard deviation of the S(t) in breath-hold observed at the intrafraction level is a bit higher than the one obtained without the patient and this can be justified by the presence of a small residual tumor motion as heartbeat. CONCLUSION: The technique is simple and can be implemented for routine use in a busy clinic.

Dynamic conformal arc therapy: transmitted signal in vivo dosimetry.

A method for the determination of the in vivo isocenter dose, D(iso), has been applied to the dynamic conformal are therapy (DCAT) for thoracic tumors. The method makes use of the transmitted signal, S(t,alpha), measured at different gantry angles, a, by a small ion chamber positioned on the electronic portal imaging device. The in vivo method is implemented by a set of correlation functions obtained by the ratios between the transmitted signal and the midplane dose in a solid phantom, irradiated by static fields. The in vivo dosimetry at the isocenter for the DCAT requires the convolution between the signals, S(t,alpha), and the dose reconstruction factors, C(alpha), that depend on the patient's anatomy and on its tissue inhomogeneities along the beam central axis in the a direction. The C(alpha) factors are obtained by processing the patient's computed tomography scan. The method was tested by taking measurements in a cylindrical phantom and in a Rando Alderson phantom. The results show that the difference between the convolution calculations and the phantom measurements is within +/-2%. The in vivo dosimetry of the stereotactic DCAT for six lung tumors, irradiated with three or four arcs, is reported. The isocenter dose up to 17 Gy per therapy fraction was delivered on alternating days for three fractions. The agreement obtained in this pilot study between the total in vivo dose D(iso) and the planned dose D(iso,TPS) at the isocenter is +/-4%. The method has been applied on the DCAT obtaining a more extensive monitoring of possible systematic errors, the effect of which can invalidate the current therapy which uses a few high-dose fractions.

Application of a practical method for the isocenter point in vivo dosimetry by a transit signal.

This work reports the results of the application of a practical method to determine the in vivo dose at the isocenter point, D(iso), of brain thorax and pelvic treatments using a transit signal S(t). The use of a stable detector for the measurement of the signal S(t) (obtained by the x-ray beam transmitted through the patient) reduces many of the disadvantages associated with the use of solid-state detectors positioned on the patient as their periodic recalibration, and their positioning is time consuming. The method makes use of a set of correlation functions, obtained by the ratio between S(t) and the mid-plane dose value, D(m), in standard water-equivalent phantoms, both determined along the beam central axis. The in vivo measurement of D(iso) required the determination of the water-equivalent thickness of the patient along the beam central axis by the treatment planning system that uses the electron densities supplied by calibrated Hounsfield numbers of the computed tomography scanner. This way it is, therefore, possible to compare D(iso) with the stated doses, D(iso,TPS), generally used by the treatment planning system for the determination of the monitor units. The method was applied in five Italian centers that used beams of 6 MV, 10 MV, 15 MV x-rays and (60)Co gamma-rays. In particular, in four centers small ion-chambers were positioned below the patient and used for the S(t) measurement. In only one center, the S(t) signals were obtained directly by the central pixels of an EPID (electronic portal imaging device) equipped with commercial software that enabled its use as a stable detector. In the four centers where an ion-chamber was positioned on the EPID, 60 pelvic treatments were followed for two fields, an anterior-posterior or a posterior-anterior irradiation and a lateral-lateral irradiation. Moreover, ten brain tumors were checked for a lateral-lateral irradiation, and five lung tumors carried out with three irradiations with different gantry angles were followed. One center used the EPID as a detector for the S(t) measurement and five pelvic treatments with six fields (many with oblique incidence) were followed. These last results are reported together with those obtained in the same center during a pilot study on ten pelvic treatments carried out by four orthogonal fields. The tolerance/action levels for every radiotherapy fraction were 4% and 5% for the brain (symmetric inhomogeneities) and thorax/pelvic (asymmetric inhomogeneities) irradiations, respectively. This way the variations between the total measured and prescribed doses at the isocenter point in five fractions were well within 2% for the brain treatment, and 4% for thorax/pelvic treatments. Only 4 out of 90 patients needed new replanning, 2 patients of which needed a new CT scan.

Breast in vivo dosimetry by a portal ionization chamber.

This work reports a practical method for the determination of the in vivo breast middle dose value, D(m) on the beam central axis, using a signal S(t), obtained by a small thimble ion chamber positioned at the center of the electronic portal imaging device, and irradiated by the x-ray beam transmitted through the patient. The use of a stable ion chamber reduces many of the disadvantages associated with the use of diodes as their periodic recalibration and positioning is time consuming. The method makes use of a set of correlation functions obtained by the ratios S(t)/D(m), determined by irradiating cylindrical water phantoms with different diameters. The method proposed here is based on the determination of the water-equivalent thickness of the patient, along the beam central axis, by the treatment planning system that makes use of the electron densities obtained by a computed tomography scanner. The method has been applied for the breast in vivo dosimetry of ten patients treated with a manual intensity modulation with four asymmetric beams. In particular, two tangential rectangular fields were first delivered, thereafter a fraction of the dose (typically less than 10%) was delivered with two multi leaf-shaped beams which included only the mammarian tissue. Only the two rectangular fields were tested and for every checked field five measurements were carried out. Applying a continuous quality assurance program based on the tests of patient setup, machine settings and dose planning, the proposed method is able to verify agreements between the computed dose D(m,TPS) and the in vivo dose value D(m), within 4%.

In vivo dosimetry by an aSi-based EPID.

A method for the in vivo determination of the isocenter dose, Diso, and mid-plane dose, Dm, using the transmitted signal St measured by 25 central pixels of an aSi-based EPID is here reported. The method has been applied to check the conformal radiotherapy of pelvic tumors and supplies accurate in vivo dosimetry avoiding many of the disadvantages associated with the use of two diode detectors (at the entrance and exit of the patient) as their periodic recalibration and their positioning. Irradiating water-equivalent phantoms of different thicknesses, a set of correlation functions F(w, l) were obtained by the ratio between St and Dm as a function of the phantom thickness, w, for a different field width, l. For the in vivo determination of Diso and Dm values, the water-equivalent thickness of the patients (along the beam central axis) was evaluated by means of the treatment planning system that uses CT scans calibrated in terms of the electron densities. The Diso and Dm values experimentally determined were compared with the stated doses D(iso,TPS) and D(m,TPS), determined by the treatment planning system for ten pelvic treatments. In particular, for each treatment four fields were checked in six fractions. In these conditions the agreement between the in vivo dosimetry and stated doses at the isocenter point were within 3%. Comparing the 480 dose values obtained in this work with those obtained for 30 patients tested with a similar method, which made use of a small ion-chamber positioned on the EPIDs to obtain the transmitted signal, a similar agreement was observed. The method here proposed is very practical and can be applied in every treatment fraction, supplying useful information about eventual patient dose variations due to the incorrect application of the quality assurance program based on the check of patient setup, machine setting, and calculations.